In an animal model of pancreatic ductal adenocarcinoma, the combination therapy of trametinib and palbociclib induced tumour cell senescence and resulted in a significant secretion of SASP factors, including pro‐angiogenic factors (VEGF, PDGFA/B, FGF2), which in turn activated vascular endothelial cells and promoted vascular remodelling.50 Here, FGF2 is linked to neoplasm.